

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
FOR THE PERIOD ENDED 30 NOVEMBER 2022

	Current Quarter Ended 30-Nov-2022 RM'000	Comparative Quarter Ended 30-Nov-2021 RM'000	Cumulative Year To Date 30-Nov-2022 RM'000	Cumulative Year To Date 30-Nov-2021 RM'000
Income				
Revenue	1,339	3,012	2,394	10,049
Cost of sales	(1,219)	(2,708)	(2,137)	(8,582)
Gross Profit	<u>120</u>	<u>304</u>	<u>257</u>	<u>1,467</u>
Other income	49	17	140	209
Total Income	1,388	3,029	2,534	10,258
Expenses				
Selling and distribution	(2)	(1,388)	(5)	(1,406)
Administrative and general expenses	(704)	(729)	(1,232)	(1,236)
Profit / (Loss) from Operations (EBITA)	<u>(537)</u>	<u>(1,796)</u>	<u>(840)</u>	<u>(966)</u>
Amortisation of Intangible Assets	(657)	(913)	(1,314)	(1,826)
Depreciation	(45)	(106)	(90)	(211)
Profit / (Loss) Before Interest and Taxes (EBIT)	<u>(1,239)</u>	<u>(2,815)</u>	<u>(2,244)</u>	<u>(3,003)</u>
ESOS Expenses	(1,771)	(361)	(1,771)	(361)
Profit / (Loss) Before Interest and Taxes	<u>(3,010)</u>	<u>(3,176)</u>	<u>(4,015)</u>	<u>(3,364)</u>
Finance Cost	(33)	(24)	(63)	(48)
Profit / (Loss) before Tax	<u>(3,043)</u>	<u>(3,200)</u>	<u>(4,078)</u>	<u>(3,412)</u>
Profit / (Loss) before tax is stated after charging/(crediting):-				
Interest income	(35)	(31)	(61)	(69)
Depreciation and amortisation	702	1,019	1,404	2,037
ESOS expenses	1,771	361	1,771	361
Foreign exchange (gain) / loss	96	9	49	57
Income tax expense	-	-	-	-
Profit / (Loss) for the period	<u>(3,043)</u>	<u>(3,200)</u>	<u>(4,078)</u>	<u>(3,412)</u>
Foreign currency translation	(81)	353	145	524
Total Comprehensive Profit / (Loss)	<u>(3,124)</u>	<u>(2,847)</u>	<u>(3,933)</u>	<u>(2,888)</u>
Attributable to :-				
Owners of the Company	(3,043)	(3,200)	(4,078)	(3,412)
Non-Controlling Interests	-	-	-	-
	<u>(3,043)</u>	<u>(3,200)</u>	<u>(4,078)</u>	<u>(3,412)</u>
Total comprehensive profit / (loss) attributable to:-				
Owners of the Company	(3,124)	(2,847)	(3,933)	(2,888)
Non-Controlling Interests	-	-	-	-
	<u>(3,124)</u>	<u>(2,847)</u>	<u>(3,933)</u>	<u>(2,888)</u>
Earnings / (Loss) per share - Basic (sen)	(0.49)	(0.51)	(0.66)	(0.55)
- Diluted (sen)	(0.48)	(0.49)	(0.63)	(0.52)

Note:

The Condensed Consolidated Statements of Comprehensive Income should be read in conjunction with the audited financial statements for the period ended 31 May 2022 and the accompanying explanatory notes attached to the interim financial statements.

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 NOVEMBER 2022

	As At 30 Nov 2022 RM'000	As At 31 May 2022 RM'000
<u>ASSETS</u>		
Non-Current Assets		
Property, Plant and Equipment	46	54
Right-of-use Assets	400	13
Intangible Assets	6,281	7,595
Trade Receivables	7,305	-
Total Non-Current Assets	<u>14,032</u>	<u>7,662</u>
Current Assets		
Trade Receivables	4,515	11,287
Other Receivables	109	101
Tax Recoverable	665	610
Deposits, Cash and Bank Balances	15,637	15,487
Total Current Assets	<u>20,926</u>	<u>27,485</u>
Total Assets	<u>34,958</u>	<u>35,147</u>
<u>EQUITY AND LIABILITIES</u>		
Capital and Reserves		
Share Capital	45,912	45,912
Reserves	(22,674)	(20,512)
Total Equity	<u>23,238</u>	<u>25,400</u>
Non-Current Liabilities		
Trade and Other Payables	31	-
Total Non-Current Liabilities	<u>31</u>	<u>-</u>
Current Liabilities		
Trade Payables	9,975	9,493
Other Payables	1,304	240
Leased Liabilities	410	14
Bank Overdraft	-	-
Total Current Liabilities	<u>11,689</u>	<u>9,747</u>
Total Liabilities	<u>11,720</u>	<u>9,747</u>
Total Equity and Liabilities	<u>34,958</u>	<u>35,147</u>
Net Assets Per Share Attributable to owners of the Company (Sen)	4	4

Note:

The Condensed Consolidated Statement of Financial Position should be read in conjunction with the audited financial statements for the year ended 31 May 2022 and the accompanying explanatory notes attached to the interim financial statements.

UCREST BERHAD

(Company No.: 420056-K)

**CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD ENDED 30 NOVEMBER 2022**

	Share Capital RM'000	Foreign Currency translation Reserve RM'000	ESOS Reserve RM'000	Accumulated Loss RM'000	Equity Attributable to the Owners of the Company RM'000	Total Equity RM'000
<u>Quarter ended 30 Nov 2022</u>						
Balance as at 1 Jun 2022 (Audited), As previously stated	45,912	879	6,595	(27,986)	25,400	25,400
Issuance of shares	-	-	-	-	-	-
Share options granted under ESOS	-	-	1,771	-	1,771	1,771
Lapsed share options	-	-	(6,468)	6,468	-	-
Profit/(loss) for the period	-	145	-	(4,078)	(3,933)	(3,933)
Comprehensive profit/(loss) for the period	-	145	(4,697)	2,390	(2,162)	(2,162)
Balance as at 30 Nov 2022 (Unaudited)	45,912	1,024	1,898	(25,596)	23,238	23,238

Note:

The condensed consolidated statement of changes in equity should be read in conjunction with the audited financial statements for the year ended 31 May 2022 and the accompanying notes attached to the interim financial statements.

**CONDENSED CONSOLIDATED CASH FLOW STATEMENT
FOR THE PERIOD ENDED 30 NOVEMBER 2022**

	6 Months to date ended 30/11/2022 RM'000	12 Months to date ended 31/05/2022 RM'000
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit / (Loss) before tax	(4,078)	(35,129)
Adjustments for:		
Amortisation of intangible assets	1,314	3,653
Depreciation of property, plant and equipment	11	265
Depreciation of right-of-use asset	79	158
Impairment loss on intangible assets	-	9,779
Impairment loss on trade receivables	-	13,837
Reversal of impairment loss on receivables	-	(185)
ESOS expenses	1,771	-
Finance costs	63	101
Interest income	(61)	(103)
Bad debts written off	-	(35)
Unrealised gain on foreign exchange translation	(56)	(259)
Unrealised loss on foreign exchange translation	47	259
Operating profit before changes in working capital	<u>(910)</u>	<u>(7,659)</u>
Changes in working capital:-		
Trade and other receivables	(534)	(106)
Trade and other payables	1,477	2,885
Cash used in operations	<u>33</u>	<u>(4,880)</u>
Interest received	61	103
Tax paid	<u>(55)</u>	<u>(169)</u>
Net cash generated from / (used in) operating activities	<u>39</u>	<u>(4,946)</u>
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property, plant & equipment	<u>(4)</u>	<u>(22)</u>
Net cash used in investing activities	<u>(4)</u>	<u>(22)</u>
CASH FLOWS FROM FINANCING ACTIVITIES		
Repayment to director	-	9
Repayment of lease liability	(69)	(164)
Interest paid	(10)	(3)
Net cash generated from / (used in) financing activities	<u>(79)</u>	<u>(158)</u>
NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS	(44)	(5,126)
CASH AND CASH EQUIVALENTS AT 01 JUNE	15,487	18,646
EFFECTS OF EXCHANGE RATE CHANGES	194	1,967
CASH AND CASH EQUIVALENTS AS AT END OF THE FINANCIAL PERIOD	<u>15,637</u>	<u>15,487</u>

Cash and cash equivalents

Cash and cash equivalents included in the statements of cash flows comprise the following statements of financial position amounts:

Deposits	2,849	11,439
Cash and bank balances	12,788	4,048
	<u>15,637</u>	<u>15,487</u>

Note:

The condensed consolidated cash flow statement should be read in conjunction with the audited financial statements for the year ended 31 May 2022 and the accompanying notes attached to the interim financial statements.

UCREST BERHAD

(Company No.: 420056-K)

SELECTED EXPLANATORY NOTES**1. Accounting Policies and Methods Of Computation**

The current quarter financial report ended 31 Aug 2022 is unaudited and has been prepared in accordance with Malaysian Financial Reporting Standards ("MFRS") 134 "Interim Financial Reporting" and Paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad ("Bursa Securities") for the ACE Market.

The report should be read in conjunction with the audited financial statements of the Group for the financial year ended 31 May 2022. The explanatory notes attached to the quarterly financial report provide an explanation on events and transactions that are significant to an understanding of the changes in the financial position and performance of the Group since the financial year ended 31 May 2022.

The accounting policies and methods of computation adopted by the Group in the quarterly financial report are consistent with those adopted in the audited financial statements of the Group for the financial year ended 31 May 2022.

2. Auditors' Report on Preceding Annual Financial Statements

The auditors' report on the audited financial statements for the year ended 31 May 2022 was not qualified.

3. Segmental Reporting**Geographical information**

	<u>Individual Quarter Ended</u>		<u>Individual YTD</u>	
	<u>30-Nov-22</u>	<u>30-Nov-21</u>	<u>30-Nov-22</u>	<u>30-Nov-21</u>
	<u>RM'000</u>	<u>RM'000</u>	<u>RM'000</u>	<u>RM'000</u>
Malaysia	-	2	-	128
International	1,339	3,010	2,394	9,921
Group revenue	1,339	3,012	2,394	10,049

4. Unusual Items

During the quarter under review, there were no unusual items affecting assets, liabilities, equity, net income, or cash flows of the Group.

5. Changes In Estimates Of Amount Reported Previously Affecting Current Interim Period

There are no changes in estimates of amount reported that will have a material effect in the current interim period.

6. Seasonality or Cyclicity

The operations of the Group are not subject to any seasonality or cyclicity factors.

7. Dividends Paid Or Proposed

Dividends were neither paid nor proposed during the current interim period.

8. Valuation of Property, Plant and Equipment

The Group has not carried out any valuation on its property, plant & equipment.

9. Debts and Equity Securities

There were no issuances, cancellations, repurchases, resale and repayments of debt and equity securities.

10. Change In The Composition of The Group

There has been no change in the composition of the group for the quarter review.

SELECTED EXPLANATORY NOTES**11. Discontinued Operation**

There were no discontinued operations within the activities of the Group for the quarter under review.

12. Capital Commitments

There were no capital commitments for the purchase of any property, plant and equipment or any other expenses that were not accounted for in the financial statements of the quarter under review.

13. Changes In Contingent Liabilities & Assets

There are no material contingent liabilities as at the date of this report.

14. Subsequent Events

There were no material events subsequent to the end of the reporting quarter that have not been reflected in the quarter under review.

Additional Information As Per ACE Market Listing Requirement**15. Review Of Performance**

During the current quarter under review, the Group recorded a net loss attributable to Owners of the Company of RM3.043 million.

16. Material Change In the Profit / (Loss) Before Taxation Compared To The Results of :-

	<u>Immediate Preceding Quarter</u>		<u>Individual Quarter Ended</u>		<u>Individual YTD</u>	
	<u>30-Nov-22</u>	<u>31-Aug-22</u>	<u>30-Nov-22</u>	<u>30-Nov-21</u>	<u>30-Nov-22</u>	<u>30-Nov-21</u>
	<u>RM'000</u>	<u>RM'000</u>	<u>RM'000</u>	<u>RM'000</u>	<u>RM'000</u>	<u>RM'000</u>
P/(L)BITDA	(537)	(304)	(537)	(1,796)	(840)	(966)
Less : Amortisation of intangible assets	(657)	(657)	(657)	(913)	(1,314)	(1,826)
Less : Depreciation	(45)	(45)	(45)	(106)	(90)	(211)
Less : ESOS expenses	(1,771)	-	(1,771)	(361)	(1,771)	(361)
Less : Finance cost	(33)	(30)	(33)	(24)	(63)	(48)
Profit / (Loss) before tax	<u>(3,043)</u>	<u>(1,036)</u>	<u>(3,043)</u>	<u>(3,200)</u>	<u>(4,078)</u>	<u>(3,412)</u>

The Group recorded loss before tax of RM 3.043 million in the current quarter, and loss before tax of RM 1.036 million in the immediate preceding quarter.

17. Commentary Of Prospects

With the Governments of many countries taking more responsibilities in public healthcare, healthcare for all and capitation seem to be the trend. To have the efficiency and control over the healthcare costs, the model seems to be Government paying private doctors to provide public healthcare. To reduce the overall healthcare costs, there is a shift to focus on preventive care for chronic disease patients. To improve the efficiency of the preventive care, the Group has been making significant investment in developing imedic IntelligentCMS, targeting specialist and general practitioner clinics and private hospital. imedic IntelligentCMS will have the digital telemedicine with IOMT devices and AI driven CMS(Clinic Management System). The product will be the leading telemedicine platform with AI driven CMS, probably the only 2 in 1 system that enables clinics to go digital and telemedicines. The Group continues to invest resources into developing the intelligent CMS platform and recruit and train to focus business development.

18. Profit Forecast

There was no profit forecast issued by the Group.

SELECTED EXPLANATORY NOTES

19. Taxation

There were no tax provision during the current interim period under review.

20. Unquoted Investments / Properties

There were no purchase or sales of unquoted investments or properties during the current interim period under review.

21. Purchase or Disposal of Quoted Securities

There were no purchase or disposal of quoted securities during the current interim period under review.

22. Status of Corporate Proposal

The Company had at the Annual General Meeting held on 17 November 2020 obtained the shareholders' approval for a private placement exercise to issue up to 126,857,800 new ordinary shares in the Company representing not more than twenty percent (20%) of the issued share capital of the company ("Private Placement"). Subsequently, the Company had at the Annual General Meeting held on 12 November 2021 obtained the shareholders' approval for a general mandate to issued up to ten percent (10%) of its total number of issued shares.

As at the date of this report, 42,700,000 new Ordinary Shares were issued pursuant to the Private Placement and were subsequently listed and quoted on the Ace Market of Bursa Malaysia Securities Berhad.

The details of the utilisation of proceeds from the Private Placement were as follows:-

Description	Proposed Utilisation (RM'000)	Actual Utilisation (RM'000)	Balance to be utilized (RM'000)
Working capital	20,748	7,898	12,850
Expenses for the proposed private placement	184	90	94

23. Group Borrowings and Debt Securities

There were no borrowings and debts securities for the financial quarter under review.

24. Off Balance Sheet Financial Instruments

There were no off balance sheet financial instruments as at the date of this report.

25. Material Litigation

There were no Material Litigation for the financial quarter under review.

SELECTED EXPLANATORY NOTES**26. Realised and Unrealised Profits/Losses**

On 25 March 2010, Bursa Securities issued a directive to all listed issuers pursuant to Rules 2.07 and 2.23 of Bursa Securities ACE Market Listing Requirements. The directive requires all listed issuers to disclose the breakdown of the unappropriated profits or accumulated losses as at the end of the reporting period, into realised and unrealised profits and losses.

On 20 December 2010, Bursa Securities further issued guidance on the disclose and the format period.

The breakdown of accumulated profit / (losses) of the Group as at the reporting date, into realised and unrealised losses, pursuant to the directive, is as follows:

	Group	
	<u>Unaudited</u> 30/11/2022 RM'000	<u>Audited</u> 31/05/2022 RM'000
Total accumulated profit / (losses) of UCrest Berhad and it's subsidiaries:		
- Realised	(25,645)	(27,727)
- Unrealised - in respect of other items of income and expense	49	(259)
Total Group accumulated profit as per consolidated accounts	<u>(25,596)</u>	<u>(27,986)</u>

The determination of realised and unrealised losses is based on the Guidedance of Special Matter No.1, Determination of Realised and Unrealised Profits or Losses in the Context of Disclosure Pursuant to Bursa Malaysia Securities Berhad Listing Requirements, issued by the Malaysian Institute of Accountants on 20 December 2010.

The disclosure of realised and unrealised losses above is solely for complying with the disclosure requirements stipulated in the directive of Bursa Malaysia and should not be applied for any other purposes.

27. Dividends Payable

The Board of Directors does not recommend any interim dividends for the current quarter ended 30 November 2022.

28. Earnings / (Loss) Per Share**(a) Basic**

The basic earnings / (loss) per share for the quarter and cumulative year to date are computed as follow:

	<u>Individual quarter ended</u>		<u>Cumulative YTD</u>	
	<u>Unaudited</u> 30-Nov-22	<u>Unaudited</u> 30-Nov-21	<u>Unaudited</u> 30-Nov-22	<u>Audited</u> 30-Nov-21
Net profit / (loss) attributable to owners of the company (RM'000)	(3,043)	(3,200)	(4,078)	(3,412)
Weighted average number of ordinary shares in issue ('000)	621,877	621,877	621,877	621,877
Basic earnings / (loss) per share (sen)	<u>(0.49)</u>	<u>(0.51)</u>	<u>(0.66)</u>	<u>(0.55)</u>

(b) Diluted

The diluted earning / (loss) per share for the quarter and cumulative year to date are computed as follow:

	<u>Individual quarter ended</u>		<u>Cumulative YTD</u>	
	<u>Unaudited</u> 30-Nov-22	<u>Unaudited</u> 30-Nov-21	<u>Unaudited</u> 30-Nov-22	<u>Audited</u> 30-Nov-21
Net profit / (loss) attributable to owners of the company (RM'000)	(3,043)	(3,200)	(4,078)	(3,412)
Dilutive shares on option outstanding ('000)	632,949	652,373	642,630	647,417
Diluted earnings / (loss) per share (sen)	<u>(0.48)</u>	<u>(0.49)</u>	<u>(0.63)</u>	<u>(0.52)</u>